iTeos Therapeutics, Inc. (NasdaqGM: ITOS)
Health Care · Biotechnology · US
$—
— today · — 1Y
iTeos Therapeutics, Inc. (NasdaqGM: ITOS) operates in the Biotechnology industry within the Health Care sector.
trading between 10.11 and 10.20.
Tweenvest scores iTeos Therapeutics, Inc. across four factors: quality 33/100. Its strongest factor is quality.
ITOS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $0.00
- P/E
- —
- EPS
- -4.68
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $10.20
- 52-week low
- $10.11
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 173
- Next earnings
- —
About iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients. The company's pipeline includes two principal investigational drugs: inupadenant, a small molecule designed as an antagonist of adenosine A2AR, which is currently undergoing Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT (T-cell immunoreceptor with Ig and ITIM domains), presently in Phase 1/2 clinical assessment. Furthermore, EOS-448's mechanism involves engaging the Fc gamma receptor (FcγR) to activate dendritic cells and macrophages, thereby promoting antibody-dependent cellular cytotoxicity (ADCC). Established in 2011, iTeos Therapeutics, Inc. is based in Watertown, Massachusetts.
- ISIN
- US46565G1040
- Founded
- 2011
- Listed since
- Jul 24, 2020
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.39 | +0.23% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $444.99 | +0.62% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.50 | -0.06% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $154.90 | -2.47% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.